HomeAI · summaries
Storia in 3 fonti
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and Abbisko.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
BridgeBio gets funding for drug launch; United buys into cell therapy
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
- ·
endpoints.news
Angitia ends Phase 3 in disc disease; Abivax raises $800M on colitis data
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal with QuantumCell.
